Divalproex sodium (Depakote ER) vs valproate
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: GABAergic neurotransmission · full Epilepsy pipeline
Divalproex sodium (Depakote ER)
Marketed by AbbVie
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
valproate
Rights held by AbbVie and partners; US product discontinued
NCT00004817 · Phase 3 · completed
The registry protocol outline and the published report (Temkin 1999) describe a randomized, double-blind, parallel-group trial: 379 patients were assigned to a 1-week course of phenytoin or a 1-month or 6-month course of valproate. The primary outcomes were seizure rates, which are clinical endpoints. Valproate did not prevent early or late post-traumatic seizures better than phenytoin, and mortality trended higher with valproate (13.4% vs 7.2%, p=0.07).
Reported efficacy
Phase III NINDS trial (Temkin et al.): valproate did not reduce early or late post-traumatic seizure rates vs phenytoin control, and showed a trend toward higher mortality (13.4% vs 7.2%). (missed)
Result source: NCT00004817
Results for Epilepsy
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Divalproex sodium (Depakote ER) | valproate |
|---|---|---|
| Seizure frequency, % change | —Not reported | —Not posted · NCT00236717 |
| 50% responder rate | —Not reported | —Not posted · NCT00236717 |
| Seizure freedom | —Not reported | —Not posted · NCT00236717 |
Seizure frequency, % change
- Divalproex sodium (Depakote ER)
- —Not reported
- valproate
- —Not posted · NCT00236717
50% responder rate
- Divalproex sodium (Depakote ER)
- —Not reported
- valproate
- —Not posted · NCT00236717
Seizure freedom
- Divalproex sodium (Depakote ER)
- —Not reported
- valproate
- —Not posted · NCT00236717
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Divalproex sodium (Depakote ER): registry results are on file for Epilepsy, but their comparison mappings are not yet available.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Divalproex sodium (Depakote ER): 0 of 4 rows · valproate: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | valproate |
|---|---|
| Dropout rate | 0.7% NCT00088452 · Phase 3 · Absence Seizures, Epilepsy · phase 3 |
| Discontinued due to AEs | — NCT00088452 · Phase 3 · Absence Seizures, Epilepsy · phase 3 |
| Serious AEs | 1.4% NCT00088452 · Phase 3 · Absence Seizures, Epilepsy · phase 3 |
| Most frequent reported AEs | fatigue 12.2% hostility 12.2% personality change 10.9% NCT00088452 · Phase 3 · Absence Seizures, Epilepsy · phase 3 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
valproate
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Divalproex sodium (Depakote ER)'s landscape · valproate's landscape